Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Once-daily hydromorphone PR tablets XL versus twice-daily Palladon retard in chronic severe cancer or non-cancer pain
2011-004471-37Phase 3Completed
- Sponsor
- Develco Pharma
- Start
- Oct 2011
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of hydromorphone in chronic pain and cancer pain (2 arms), sponsored by Develco Pharma. Primary endpoint: Mean current pain intensity. Started Oct 2011; status: completed.
02
Drugs
hydromorphone
03
Conditions
chronic paincancer pain
Beyond the preview
Go deeper on 2011-004471-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-004471-37.